Significant improvements in psychological burden scores were noted among patients with pancreatobiliary cancers and their caregivers after participating in a support group.
The approval is supported by data from the phase 3 BEACON CRC trial in adults with BRAF V600E mutation-positive metastatic colorectal cancer with disease progression.
The 2-year actuarial rate of local recurrence was 4.8%.
The application is supported by data from the phase 3 RATIONALE 302 trial.
The objective response rate was 23.1%, and the disease control rate was 84.3%.